Bayer AG NA (BAYGn)

50.36
-0.71(-1.39%)
  • Volume:
    2,977,898
  • Bid/Ask:
    50.33/50.39
  • Day's Range:
    50.30 - 50.84
  • Type:Equity
  • Market:Germany
  • ISIN:DE000BAY0017
  • WKN:BAY001

BAYGn Overview

Prev. Close
51.07
Day's Range
50.3-50.84
Revenue
40.88B
Open
50.41
52 wk Range
39.91-59.55
EPS
-15.11
Volume
2,977,898
Market Cap
49.51B
Dividend (Yield)
2.00
(3.96%)
Average Volume (3m)
2,760,755
P/E Ratio
-
Beta
1.31
1-Year Change
-12.69%
Shares Outstanding
982,424,082
Next Earnings Date
04 Aug 2021
What is your sentiment on Bayer AG NA?
or
Market is currently closed. Voting is open during market hours.

Bayer AG NA News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellSellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

Bayer AG NA Company Profile

Bayer AG NA Company Profile

Employees
99329
Market
Germany

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc. and Forschungszentrum Jülich GmbH; strategic research partnership with University of Oxford to develop novel gynecological therapies; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.